Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
22.15
-0.32 (-1.42%)
At close: Jul 2, 2024, 4:00 PM
21.70
-0.45 (-2.03%)
After-hours: Jul 2, 2024, 7:35 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for NTLA stock have an average target of 66.93, with a low estimate of 29 and a high estimate of 120. The average target predicts an increase of 202.17% from the current stock price of 22.15.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NTLA stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 3 | 3 | 3 |
| Buy | 12 | 10 | 10 | 8 | 8 | 7 |
| Hold | 4 | 4 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 18 | 18 | 15 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $73 | Strong Buy | Maintains | $73 | +229.57% | Jun 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +193.45% | Jun 24, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $120 | Strong Buy | Maintains | $120 | +441.76% | Jun 24, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +193.45% | Jun 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +193.45% | Jun 4, 2024 |
Financial Forecast
Revenue This Year
72.20M
from 36.28M
Increased by 99.04%
Revenue Next Year
69.24M
from 72.20M
Decreased by -4.10%
EPS This Year
-5.26
from -5.42
EPS Next Year
-5.56
from -5.26
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 137.6M | 220.5M | 514.5M | 4.0B | 9.3B |
| Avg | 72.2M | 69.2M | 140.9M | 644.7M | 1.7B |
| Low | 39.2M | n/a | 19.6M | n/a | 44.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 279.2% | 205.4% | 643.0% | 2,722.3% | 1,345.1% |
| Avg | 99.0% | -4.1% | 103.5% | 357.6% | 162.3% |
| Low | 8.1% | - | -71.7% | - | -93.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.75 | -4.29 | -2.33 | 23.51 | 52.19 |
| Avg | -5.26 | -5.56 | -5.79 | -0.06 | 7.09 |
| Low | -5.78 | -6.73 | -8.80 | -6.50 | -4.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.